Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

258.05 +3.03 (+1.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 855,916
Open 254.97
Bid (Size) 254.47 (1)
Ask (Size) 261.00 (2)
Prev. Close 255.02
Today's Range 254.04 - 258.46
52wk Range 194.63 - 319.76
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily
Biogen Completes Acquisition of Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire

Performance

YTD
-5.35%
-5.35%
1 Month
-2.64%
-2.64%
3 Month
-8.36%
-8.36%
6 Month
-4.42%
-4.42%
1 Year
+31.83%
+31.83%

More News

Read More
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
From Biogen Inc.
Via GlobeNewswire
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
Better Buy: Biogen vs. Eli Lilly
Via The Motley Fool
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Via The Motley Fool
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Via InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
Via Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
Via InvestorPlace
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Biogen Appoints Jane Grogan as Head of Research
From Biogen Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks to Buy Now: September 2023
Via InvestorPlace
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
Via Investor's Business Daily
The 7 Most Promising Momentum Stocks to Own Now
Via InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
Via InvestorPlace
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.